Acesulfame Potassium vs Potassium Bromate: which is worse?

What is Acesulfame Potassium?

Acesulfame potassium (Ace-K) is a calorie-free synthetic sweetener approximately 200 times sweeter than sucrose. It contains a potassium atom bonded to an oxathiazinone dioxide ring structure. It is heat-stable and non-metabolized, passing through the body unchanged. Often blended with sucralose or aspartame to mask bitter aftertaste.

What is Potassium Bromate?

Potassium bromate (KBrO3) is an oxidizing agent used in commercial bread baking as a flour maturing agent and dough conditioner. It strengthens gluten networks, improves dough elasticity, and produces a more uniform, light-textured baked product. It is a white crystalline powder.

Documented risks

Acesulfame Potassium: The safety database for Ace-K is considered less comprehensive than that for other sweeteners. Critics have argued that the original FDA approval studies from the 1970s-1980s were insufficient in quality and length to definitively establish long-term safety. The Center for Science in the Public Interest (CSPI) has petitioned for additional testing. Two rat studies found statistically significant increases in lung tumors (in male rats) and mammary tumors at high doses. Regulatory agencies have argued these doses far exceeded typical human exposure and attributed the tumor findings to other factors. However, the question of whether Ace-K's approval studies meet modern standards has been raised by independent researchers. A 2021 study in Cell found that Ace-K and other non-nutritive sweeteners altered gut microbiome composition and affected glucose tolerance in some human participants. Ace-K specifically was associated with changes in gut bacteria that correlated with glycemic effects. Neurological concerns: some animal studies suggest Ace-K may affect brain neurotransmitter systems. A 2013 study in PLoS ONE found that Ace-K consumption in pregnant mice altered offspring postnatal taste preference and increased weight gain, suggesting potential transgenerational effects. These findings were at doses exceeding typical human intake. Endocrine disruption potential has been raised in some in vitro studies, but comprehensive human data are lacking.

Potassium Bromate: Potassium bromate is classified by the International Agency for Research on Cancer (IARC) as Group 2B — a possible human carcinogen — based on sufficient evidence in animals. This classification was formalized in 1999. The landmark toxicology study is Kurokawa et al. (1990), published in Environmental Health Perspectives (PMC1567851), which demonstrated that KBrO3 induces renal cell tumors (kidney cancer), mesotheliomas of the peritoneum, and follicular cell tumors of the thyroid in rats. Importantly, the researchers demonstrated KBrO3 is a complete carcinogen — it possesses both tumor-initiating and tumor-promoting activities for renal tumorigenesis. The mechanism of carcinogenicity involves generation of reactive oxygen species, particularly hydroxyl radicals and superoxide radicals. These radicals cause oxidative DNA damage, specifically 8-hydroxydeoxyguanosine (8-OHdG) formation in rat kidney cells — a well-characterized biomarker of oxidative DNA damage. California declared potassium bromate a known carcinogen under Proposition 65 in 1991, requiring cancer warning labels on California products containing it. Multiple advocacy organizations including CSPI (1999 petition) and EWG (2015 petition) have petitioned the FDA for a federal ban. As of 2025, the FDA has urged voluntary industry elimination since the early 1990s but has not issued a formal ban. Nephrotoxicity from high-dose potassium bromate is well documented in case reports of accidental or intentional poisonings: it causes irreversible renal tubular necrosis, permanent deafness (cochlear damage), and blindness (optic nerve damage). These effects occur at doses far above food consumption scenarios but demonstrate the compound's acute toxicological potency. FDA testing in 1999 found residual potassium bromate above expert-recommended safe limits in more than half of 17 tested bread and roll products, demonstrating that the 'it bakes off completely' argument does not always hold in commercial practice.